SLC34A2 and ovarian cancer: For example, FGF18 and WNT7A were proposed to promote ovarian tumor aggressiveness (Wei et al., 2013; Yoshioka et al., 2012); FOLR1 and CDH6 were recently highlighted as antigens to design antibody-drug conjugates against ovarian cancer (Bialucha et al., 2017; Moore et al., 2017); CLDN16 and SLC34A2 represented ovarian cancer-specific transcripts (HOSTs) (Rangel et al., 2003); SOX17 and SPON1 were ambiguously tied to ovarian carcinomas (Bapat et al., 2010; Pyle-Chenault et al., 2005).